Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11351 publications

Immunotherapies in progressive multiple sclerosis.

Immunotherapies in progressive multiple sclerosis.

Journal: Handbook of clinical neurology
Published: January 12, 2026

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.

Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 27, 2025

Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study.

Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 26, 2025

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.

Journal: Neurology
Published: December 22, 2025

Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?

Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?

Journal: Neurology
Published: December 22, 2025

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 20, 2025

Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis.

Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 17, 2025

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Journal: Neurology
Published: December 15, 2025

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Dissecting definitions of disability accrual in relapsing multiple sclerosis-Have we reached standardization yet?

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 06, 2025

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.

Journal: Neurology
Published: November 24, 2025

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.

Journal: Neurology
Published: November 24, 2025

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis.

Differences in the Neural Substrate for Physical and Mental Quality of Life in Patients With Multiple Sclerosis.

Journal: Brain and behavior
Published: November 22, 2025
Showing 1-12 of 11,351

Last Updated: 02/24/2026